Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.
Mitsui Y, Shiina H, Kato T, Maekawa S, Hashimoto Y, Shiina M, Imai-Sumida M, Kulkarni P, Dasgupta P, Wong RK, Hiraki M, Arichi N, Fukuhara S, Yamamura S, Majid S, Saini S, Deng G, Dahiya R, Nakajima K, Tanaka Y. Mitsui Y, et al. Among authors: hiraki m. Mol Cancer Res. 2017 Jul;15(7):884-895. doi: 10.1158/1541-7786.MCR-16-0444. Epub 2017 Feb 27. Mol Cancer Res. 2017. PMID: 28242813 Free PMC article.
Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
Mitsui Y, Hirata H, Arichi N, Hiraki M, Yasumoto H, Chang I, Fukuhara S, Yamamura S, Shahryari V, Deng G, Saini S, Majid S, Dahiya R, Tanaka Y, Shiina H. Mitsui Y, et al. Among authors: hiraki m. Oncotarget. 2015 Apr 20;6(11):9577-91. doi: 10.18632/oncotarget.3445. Oncotarget. 2015. PMID: 25797254 Free PMC article.
Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
Mitsui Y, Shiina H, Hiraki M, Arichi N, Hiraoka T, Sumura M, Honda S, Yasumoto H, Igawa M. Mitsui Y, et al. Among authors: hiraki m. Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):487-96. doi: 10.1158/1055-9965.EPI-11-0970. Epub 2012 Jan 13. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22246902
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.
Arichi N, Mitsui Y, Hiraki M, Nakamura S, Hiraoka T, Sumura M, Hirata H, Tanaka Y, Dahiya R, Yasumoto H, Shiina H. Arichi N, et al. Among authors: hiraki m. Oncoscience. 2015 Mar 2;2(2):193-204. doi: 10.18632/oncoscience.136. eCollection 2015. Oncoscience. 2015. PMID: 25859560 Free PMC article.
237 results